ESSA Pharma | 8-K: ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024
ESSA Pharma | 10-Q: Quarterly report
ESSA Pharma | 4: Statement of changes in beneficial ownership of securities-Officer Virsik Peter
ESSA Pharma | 4: Statement of changes in beneficial ownership of securities-Director Glickman Richard M
ESSA Pharma | 4: Statement of changes in beneficial ownership of securities-Officer Virsik Peter
ESSA Pharma | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
ESSA Pharma | 144: Notice of proposed sale of securities pursuant to Rule 144
ESSA Pharma | 4: Statement of changes in beneficial ownership of securities-Director ZWEIFACH SANFORD S
ESSA Pharma | 4: Statement of changes in beneficial ownership of securities-Director Thorell Marella
ESSA Pharma | 4: Statement of changes in beneficial ownership of securities-Director Sollis Gary
ESSA Pharma | 4: Statement of changes in beneficial ownership of securities-Director Requadt Scott
ESSA Pharma | 4: Statement of changes in beneficial ownership of securities-Director Merendino Lauren
ESSA Pharma | 4: Statement of changes in beneficial ownership of securities-Director Martin John Alexander
ESSA Pharma | 4: Statement of changes in beneficial ownership of securities-Director Kantoff Philip W.
ESSA Pharma | 4: Statement of changes in beneficial ownership of securities-Director Glickman Richard M
ESSA Pharma | 4: Statement of changes in beneficial ownership of securities-Director BERGER FRANKLIN M
ESSA Pharma | 4: Statement of changes in beneficial ownership of securities-Officer Wood David S.
ESSA Pharma | 4: Statement of changes in beneficial ownership of securities-Officer Virsik Peter
ESSA Pharma | 4: Statement of changes in beneficial ownership of securities-Officer Parkinson David Ross
ESSA Pharma | 4: Statement of changes in beneficial ownership of securities-Officer Cesano Alessandra
No Data